NEWS & EVENTS

22. 3. 30.

Dr. Sun Kim was invited to serve on the IEEE/ACM TCBB Steering Committee as an ACM representative.

Dr. Sun Kim was invited to serve on the IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB) Steering Committee as an Association for Computing Machinery (ACM) representative from January 1, 2022.

Dr. Sun Kim was invited to serve on the IEEE/ACM TCBB Steering Committee as an ACM representative.

22. 3. 13.

2022년 제1기 정기주주총회 소집 공고

주주 각위의 건승을 경하드립니다.
당사 정관 제24조의 규정에 의거 다음과 같이 2022년도 제1기 정기주주총회를 개최하오니 참석하여 주시기 바랍니다.

2022년 제1기 정기주주총회 소집 공고

11/11/2021

Dr. Sun Kim’s work on DL modeling of GPCR protein family hierarchy was selected by Faculty Opinions

Dr. Sun Kim’s work on deep learning modeling of GPCR protein family hierarchy was selected by Faculty Opinions.

Dr. Sun Kim’s work on DL modeling of GPCR protein family hierarchy was selected by Faculty Opinions

11/03/2021

Dr. Sun Kim was awarded prestigious “Ilchun Memorial Lecture”.

Dr. Sun Kim was awarded prestigious “Ilchun Memorial Lecture” and gave a lecture “Modern AI Technologies: Innovative Toolkits for the Investigation of Fundamental Questions in Molecular Biology” at the international conference, organized by the Korean Society for Molecular and Cellular Biology (KSMCB) 2021.

Dr. Sun Kim was awarded prestigious “Ilchun Memorial Lecture”.

08/26/2021

'AI platform for drug target' project launch

AIgenDrug started the 'AI ​​platform for drug target' project to provide drug target prediction service.

'AI platform for drug target' project launch

08/25/2021

Initiated a new project 'AI platform for drug toxicity' in collaboration with Seoul National University

On August 25, 2021, AIgenDrug signed an MoU with three experts at Seoul National University for the development and deployment of an AI drug toxicity prediction model.

Initiated a new project 'AI platform for drug toxicity' in collaboration with Seoul National University

08/01/2021

Welcome Dr. Sunho Lee, our new CTO

AIgenDrug is proud to announce that Dr. Sunho Lee takes the role of Vice President and Chief Technology Officer (CTO). He will lead the company’s technical strategy and business development for AI drug discovery.

Welcome Dr. Sunho Lee, our new CTO